



**Aarti Drugs Limited**

**Manufacturers of : Bulk Drugs & Chemicals**

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

**Ref: ADL/SE/2025-26/24**  
**July 18, 2025**

To,  
Listing/ Compliance Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**BSE CODE: 524348**

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited,**  
“Exchange Plaza”, Plot No. C/1,  
G Block Bandra - Kurla Complex,  
Bandra (East), Mumbai – 400051  
**NSE SYMBOL: AARTIDRUGS**

Dear Sir/Madam,

**Ref:** Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**Sub:** Press Release on Financial Results.

Please find attached herewith press release on Financial Results for the Quarter ended June 30, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**FOR AARTI DRUGS LIMITED**

**RUSHIKESH DEOLE**

**COMPANY SECRETARY & COMPLIANCE OFFICER**

ICSI M. No.: F12932



## Q1 & FY26 Business & Financial Performance

Mumbai, 18<sup>th</sup> July 2025

**Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348)**, a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announced its Unaudited Financial Results for the quarter ending 30<sup>th</sup> June 2025.

### Consolidated Financial Highlights

Particulars (In Rs. Crores)	Q1 FY26	Q1 FY25	YoY%	Q4 FY25	QoQ%
<b>Revenue</b>	<b>590.8</b>	<b>556.5</b>	<b>+6%</b>	<b>678.6</b>	<b>(13%)</b>
Gross Profit <sup>#</sup>	217.4	196.6	+11%	241.7	(10%)
<b>EBITDA*</b>	<b>74.4</b>	<b>66.1</b>	<b>+12%</b>	<b>95.2</b>	<b>(22%)</b>
<b>EBITDA Margin %</b>	<b>12.6%</b>	<b>11.9%</b>	<b>+70 bps</b>	<b>14.0%</b>	<b>(140 bps)</b>
Profit Before Tax (PBT)*	51.1	44.0	+16%	71.2	(28%)
<b>Profit After Tax (PAT)</b>	<b>54.0</b>	<b>33.3</b>	<b>+62%</b>	<b>62.8</b>	<b>(14%)</b>
<b>PAT Margin %</b>	<b>9.1%</b>	<b>6.0%</b>	<b>+310 bps</b>	<b>9.2%</b>	<b>(10 bps)</b>
EPS (in Rs.)	5.91	3.62		6.88	

<sup>#</sup> Gross Profit = Revenue - Raw Material Consumed; \*EBITDA excludes exceptional items but includes other income

### Consolidated Financial Highlights – Q1 FY26

- **Revenue** stood at Rs. 590.8 crores as against Rs. 556.5 crores, a growth of 6% YoY
- **EBITDA** stood at Rs. 74.4 crores as against Rs. 66.1 crores, a growth of 12% YoY. **EBITDA Margin** stood at 12.6%, an increase of 70 basis points
- **PAT** stood at Rs. 54.0 crores as against Rs. 33.3 crores, an increase of 62% YoY. **PAT Margin** is at 9.1%, an increase of 310 basis points

### Segmental Performance Update

Particulars (In Rs. Crores)	Q1FY26	Q1FY25	YoY%	Q4 FY25	QoQ%
API	<b>458.2</b>	442.7	+4%	553.1	(17%)
Formulations	<b>80.3</b>	70.5	+14%	64.8	+24%
Specialty Chemicals	<b>33.1</b>	26.6	+24%	39.0	(15%)
Intermediaries & Others	<b>18.9</b>	15.5	+22%	19.8	(4%)

### Standalone Business Highlights – Q1 FY26

- Revenue stood at Rs. 521.3 crores vs. Rs. 493.1 crores in Q1 FY25, growth by 6% YoY
- Standalone business contributed 86% to the consolidated revenue
- 65% of the revenues came from the domestic market and 35% from the exports market
- Domestic revenue remained flat YoY and exports increased by 18% YoY
- Within the API business, the anti-biotic therapeutic category contributed ~41%, anti-diabetic ~15%, anti-protozoal ~19%, anti-inflammatory ~12%, antifungal ~10% and the rest contributed ~4% to total API sales

**Formulation Segment Highlights**

- Revenue from formulations stood at Rs. 80.3 crores as against Rs. 70.5 crores in Q1 FY25, up 14% YoY. 57% of the revenue contribution is from exports during the quarter

**Commenting on the same, Mr. Adhish Patil, CFO & COO, of Aarti Drugs Limited said,**

"In Q1 FY26, Revenues grew by 6% YoY to Rs. 591 crores with Gross Profit Margins improving by 130 basis points YoY to 36.8%. EBITDA has increased by 12% YoY to Rs. 74 crores and EBITDA Margins improving to 12.6%. The quarter witnessed improved demand for active pharmaceutical ingredients (APIs), leading to a recovery and growth in volumes as compared to Q1FY25.

During Q1FY26 the Company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D. For FY26, we expect Capex at ~Rs. 150-200 crores.

The Company has started trial productions at its new greenfield manufacturing facility in Sayakha, Gujarat. This plant has been set up mainly for backward integration into anti-diabetic products and their intermediates, and is expected to largely serve internal requirements. This backward integration is a key strategic step that should help improve profit margins over time and reduce the risk of input costs volatility. This project will support internal requirements for our anti-diabetic product and choline chloride, contributing to backward integration, margin improvement, and supply chain de-risking.

The new greenfield Salicylic Acid plant at Tarapur is progressing well and is expected to begin contributing to the Company's financials from the third quarter onwards. While the plant faced some initial start-up issues—typical during the early stages of new projects for inhouse developed technology—these have been effectively addressed and are being implemented at the plant scale. The Company is now focused on a calibrated ramp-up of operations, with a clear roadmap to scale production to over 800 tonnes per month and further expand the installed capacity to approximately 1,600 tonnes per month by the end of FY26.

A lot of new regulated customer audits have been triggered at the Tarapur facility. We also plan to expand this facility by putting more production blocks in future.

Recently, the USA government has announced high tariffs on pharmaceutical products and APIs imported from countries like China. This move is aimed at reducing their dependence on Chinese suppliers. This has the potential to reshape global supply chains. While this may disrupt sourcing patterns for several players, it also opens up new opportunities for Indian API manufacturers.

Aarti Drugs, with a recently USFDA approved API facility and established manufacturing capabilities, is strategically positioned to meet this demand shift. The commissioning of new capacity at Sayakha and Tarapur supports this readiness and enhances the Company's ability to serve regulated export markets. Our formulation subsidiary has also got USFDA approval for its Oncology facility & UKMHRA approval for our OSD facility; alongside we are on a path to develop and register new oncology dossiers across the globe which will drive the regulated market growth from FY27 onwards.

The Company remains focused on execution, cost optimization, and product mix enhancement to drive sustainable growth and margin improvement in the coming quarters."



### **About Aarti Drugs Limited**

Aarti Drugs Limited was established in the year 1984 and forms part of \$6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 13 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 2 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

For more information, please visit [www.aartidrugs.co.in](http://www.aartidrugs.co.in)

### **Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

Company:	Investor Relations (IR)
<b>Aarti Drugs Limited</b>	<b>Strategic Growth Advisors Pvt. Ltd.</b>
	
CIN: L37060MH1984PLC055433	CIN: U74140MH2010PTC204285
<b>Mr. Rushikesh Deole</b>	<b>Mr. Deven Dhruva</b>
<a href="mailto:investorrelations@aartidrugs.com">investorrelations@aartidrugs.com</a>	<a href="mailto:deven.dhruva@sgapl.net">deven.dhruva@sgapl.net</a>
+91 22 24048199	+91 98333 73300
<a href="http://www.aartidrugs.co.in">www.aartidrugs.co.in</a>	<a href="http://www.sgapl.net">www.sgapl.net</a>